ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St
ScripWho: Merck & Co./Artiva Biotherapeutics What: Merck & Co. signed a partnership and option-to-license agreement to access Artiva’s off-the-shelf natural killer cell and chimeric antigen receptor tec